Table 1.

Expression of potential target antigens for CAR-T cell therapy of multiple myeloma

Surface antigen	Expression in multiple myeloma (% of cases)	Expression in normal hematopoietic cells	Known expression in normal solid organ tissues	References
CD70	0,2 – 42%	activated T and B cells, dendritic cells, plasma cells		[17, 18, 20]
CD56	78%, reduced in extramedullary disease	T and NK cells	neuronal cells	[21, 22]
CD44v6	43% in advanced stage	activated T cells, monocytes	keratinocytes	[27]
SLAMF7	high and uniform expression	T, B and NK cells, macrophages, dendritic cells, plasma cells		[30, 32]
CD38	high and uniform expression	activated T cells, NK cells, plasma cells, early B cells, immature myeloid and erythroid cells, thymocytes	prostatic epithelium, pancreatic islet cells, cerebellar Purkinje cells	[35–37]
CD138	high expression	plasma cells	liver, skin and glandular epithelial cells	[45, 47]
κ light chain	expression on κ-restricted disease propagating cells	mature B cells		[77]
CD19	low expression in most cases; potentially mostly on disease propagating cells	B cells		[51]
BCMA	60 – 100%	mature B cells, plasma cells		[53, 78]

Abbreviations: NK – natural killer; SLAMF7 - signaling lymphocytic activation molecule family member 7; BCMA – B cell maturation antigen